Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $814,000.

  • Arrowhead Pharmaceuticals' Gains from Investment Securities rose 110.77% to $733,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 60.04%. This contributed to the annual value of $814,000 for FY2025, which is 121.74% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $814,000 for FY2025, which was up 121.74% from -$3.7 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Gains from Investment Securities registered a high of $3.5 million during FY2021, and its lowest value of -$4.4 million during FY2022.
  • For the 2-year period, Arrowhead Pharmaceuticals' Gains from Investment Securities averaged around -$1.5 million, with its median value being -$1.5 million (2024).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 228.23% in 2022, then soared by 121.74% in 2025.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $3.5 million in 2021, then crashed by 228.23% to -$4.4 million in 2022, then reached -$3.7 million in 2024, then soared by 121.74% to $814,000 in 2025.